riluzole has been researched along with Anxiety Neuroses in 8 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous behavioral pharmacology studies involving rodents suggested riluzole had potential to be an ideal psychotropic drug for psychiatric disorders with anxiety or fear as primary symptoms." | 9.41 | Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review. ( Akagi, K; Furuie, H; Kawashima, T; Kawashima, Y; Kuniishi, H; Noda, T; Yamada, M, 2023) |
| "Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate." | 6.44 | Riluzole in the treatment of mood and anxiety disorders. ( Banasr, M; Bloch, M; Coric, V; Krystal, JH; Pittenger, C; Sanacora, G, 2008) |
| "Previous behavioral pharmacology studies involving rodents suggested riluzole had potential to be an ideal psychotropic drug for psychiatric disorders with anxiety or fear as primary symptoms." | 5.41 | Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review. ( Akagi, K; Furuie, H; Kawashima, T; Kawashima, Y; Kuniishi, H; Noda, T; Yamada, M, 2023) |
| "Riluzole appears to be an effective, well-tolerated, and rapidly acting anxiolytic medication for some patients with generalized anxiety disorder." | 2.71 | Open-label trial of riluzole in generalized anxiety disorder. ( Amiel, JM; Coplan, JD; Fitterling, HA; Gorman, JM; Mathew, SJ; Sackeim, HA, 2005) |
| "Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate." | 2.44 | Riluzole in the treatment of mood and anxiety disorders. ( Banasr, M; Bloch, M; Coric, V; Krystal, JH; Pittenger, C; Sanacora, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kawashima, Y | 1 |
| Yamada, M | 2 |
| Furuie, H | 1 |
| Kuniishi, H | 1 |
| Akagi, K | 1 |
| Kawashima, T | 1 |
| Noda, T | 1 |
| Rapp, A | 1 |
| Dodds, A | 1 |
| Walkup, JT | 1 |
| Rynn, M | 1 |
| Pittenger, C | 1 |
| Coric, V | 1 |
| Banasr, M | 1 |
| Bloch, M | 1 |
| Krystal, JH | 1 |
| Sanacora, G | 1 |
| Pollack, MH | 1 |
| Abdallah, CG | 2 |
| Coplan, JD | 4 |
| Jackowski, A | 2 |
| Sato, JR | 2 |
| Mao, X | 3 |
| Shungu, DC | 3 |
| Mathew, SJ | 4 |
| Amiel, JM | 1 |
| Fitterling, HA | 1 |
| Sackeim, HA | 1 |
| Gorman, JM | 1 |
| Price, RB | 1 |
| Smith, EL | 1 |
| Charney, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder[NCT03017508] | Phase 2/Phase 3 | 22 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Measure Description: In the Visual Analogue Scale (VAS) participants are presented with a straight horizontal line of 100 mm in length and asked to mark the placement that would best describe the intensity of the anxiety felt at that moment. The left end (0mm) represents no anxiety and the right end (100mm) represents the worst anxiety ever felt by the participant.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks, generating a numerical score along a continuum" (NCT03017508)
Timeframe: up to 60 minutes
| Intervention | millimeters (units on a scale) (Mean) |
|---|---|
| BHV-0223 (Sublingual Riluzole) | 54.3 |
| Placebo | 62.6 |
4 reviews available for riluzole and Anxiety Neuroses
| Article | Year |
|---|---|
Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.
Topics: Anxiety; Anxiety Disorders; Fear; Humans; Obsessive-Compulsive Disorder; Riluzole | 2023 |
Treatment of pediatric anxiety disorders.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Anxiety, Separation; Child; Cognitive Behavioral The | 2013 |
Riluzole in the treatment of mood and anxiety disorders.
Topics: Animals; Anxiety Disorders; Excitatory Amino Acid Antagonists; Humans; Models, Biological; Mood Diso | 2008 |
Refractory generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiet | 2009 |
3 trials available for riluzole and Anxiety Neuroses
| Article | Year |
|---|---|
Riluzole effect on occipital cortex: a structural and spectroscopy pilot study.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Aspartic Acid; Excitatory Amino Acid Antagonists; Fem | 2012 |
Open-label trial of riluzole in generalized anxiety disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Drug Administration Schedule; Excitatory Amino Acid Antag | 2005 |
Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Aspartic Acid; Excitatory Amino Acid Antagonists; Fem | 2008 |
1 other study available for riluzole and Anxiety Neuroses
| Article | Year |
|---|---|
A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD.
Topics: Adult; Anxiety Disorders; Aspartic Acid; Biomarkers; Female; Hippocampus; Humans; Male; Organ Size; | 2013 |